DLL3 expression in Large Cell Neuroendocrine Carcinoma (LCNEC) and Association with Molecular Subtypes and Neuroendocrine Profile
Large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are aggressive neuroendocrine tumors with poor survival rates [1 –3]. For stage IV SCLC, treatment has not advanced significantly over the last decades and consists of palliative chemotherapy. The same applies to stage IV LCNEC, were no standard treatment exists and palliative chemotherapy with SCLC and non-small cell lung cancer (NSCLC) regimens are both deeme d appropriate . Recently, targeted therapy focusing on delta like protein 3 (DLL3) has received attention to improve outcomes for SCLC and LCNEC .
CONCLUSIONS: Genomic subtyping has potentials in prognostication and therapeutic decision-making for patients with LCNEC and cfDNA analysis may be a reliable alternative for genomic profiling of LCNEC. PMID: 31694833 [PubMed - as supplied by publisher]
Authors: Polański J, Jankowska-Polańska B, Mazur G, Chabowski M Abstract Behavioral cognitive therapy is recommended for lung cancer-related pain. The aim of the study was to analyze the strategies of coping with pain in relation to the histological type of lung cancer. The study included 257 lung cancer patients, divided into small cell lung carcinoma (SCLC) group (n = 72) and non-small cell lung carcinoma (NSCLC) group (n = 185). Pain was evaluated on a visual analog scale (VAS), while pain-coping strategies with the Coping Strategies Questionnaire. The two groups differed concerning the per...
Authors: Ren A, Wen Z, Zheng L Abstract Tumor protein p53-inducible nuclear protein 1 (TP53INP1) is a tumor suppressor associated with malignant tumor metastasis. In addition, it has been reported that hsa-microRNA (miR)-3934 serves key roles in various types of lung cancer, including small-cell lung carcinomas (SCLC) and non-SCLC (NSCLC). Therefore, the present study aimed to determine the effects of miR-3934-5p on cell proliferation and apoptosis, and on sensitivity to cisplatin (DDP). Reverse transcription-quantitative polymerase chain reaction analysis and western blotting were conducted for the analysis of mRN...
Conclusions This proof-of-concept study preliminarily demonstrates the efficacy of the dual targeting 68Ga-NOTA-3P-TATE-RGD PET/CT in the evaluation of lung cancer and neuroendocrine neoplasm in a single scan.
Conclusion: IOV in target volume delineation increases during treatment, where a disparity in institutional adaptation practices adds to the conventional causes of IOV. Consensus guidelines are urgently needed. PMID: 31271079 [PubMed - as supplied by publisher]
Conclusions: This study concludes that 68Ga Pentixafor is a promising future PET molecule for imaging CXCR4 over expression reported in lung cancer and many other human malignancies. This novel PET tracer has the potential of becoming a powerful tool for monitoring therapy response to CXCR4 inhibitors and also for the development of emerging alpha/beta targeted therapies in advanced stage lung carcinoma. $$graphic_078CAB3A-2C78-49E0-8A2E-0F11F0BF0518$$
CONCLUSION: To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients' blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies. PMID: 31104010 [PubMed - as supplied by publisher]
Lung cancer is the leading cause of cancer related mortality globally and is classified as either Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC) upon pathology review. [1,2] The main histologic types of NSCLC include squamous cell carcinoma and adenocarcinoma.  The majority of patients have non-curable disease stage at the time of diagnosis. Advances in systemic treatments including chemotherapy, targeted therapies and immune check point inhibitors have improved prognosis in recent years.
Publication date: May 2019Source: Journal of the American College of Radiology, Volume 16, Issue 5, SupplementAuthor(s): Expert Panel on Thoracic Imaging:, Patricia M. de Groot, Jonathan H. Chung, Jeanne B. Ackman, Mark F. Berry, Brett W. Carter, Patrick M. Colletti, Stephen B. Hobbs, Barbara L. McComb, Benjamin Movsas, Betty C. Tong, Christopher M. Walker, Sue S. Yom, Jeffrey P. KanneAbstractLung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but oth...
Lung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non –small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, comprises about 85% of lung cancers.